Table 1 Baseline characteristics and clinical course of patients
Patient | Age (years) | Kidney transplant (years prior to COVID-19) | Concomitant diseases | Induction therapy | Immunosuppressive medication | Tacrolimus level prior to COVID-19 (ng/mL) | eGFR prior to COVID-19 (mL/min/1.73 m2) | Vaccination status (number of vaccines received) | SARS-CoV2 S1-IgG (BAU/mL) | Symptoms | NEWS 2 | Oxygen dependency | COVID-19 treatment other than nirmatrelvir / ritonavir | Clinical course and complications |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 74 | Deceased donor (3) | ADPKD, hypertensive heart disease, aortic regurgitation, cirrhosis CHILD–Pugh class A, PTDM | basiliximab | tacrolimus, azathioprine, corticosteroid | 4.9 | 55 | 3 | 171 | fatigue | 4 | no | sotrovimab | cholangiosepsis, death |
2 | 62 | ABOc living donation (5) | IgA nephropathy, PTDM, fatty liver, transplant renal artery stenosis | basiliximab | tacrolimus, mycophenolate, corticosteroid | 5.5 | 40 | 4 | negative | fatigue, fever, coughing | 4 | no | sotrovimab | improvement, no complications |
3 | 25 | ABOi living donation (0) | posterior urethral valves, hypertension | rituximab, thymoglobulin | tacrolimus, mycophenolate, corticosteroid | 6.5 | 55 | 3 | > 2180 | fatigue, fever, coughing, sore throat | 3 | no | no | improvement, no complications |
4 | 60 | ABOi living donation (4) | hypertension, hypertensive heart disease, PTDM | rituximab, basiliximab | tacrolimus, mycophenolate, corticosteroid | 6.4 | 45 | 3 | negative | fatigue, diarrhoea, coughing, vomiting, weight loss, hyponatremia, dehydration | 12 | max.8 L/min | sotrovimab, tocilizumab | improvement, no complications |